Los Angeles Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Los Angeles Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82K	Sell	335 -2,843	-89%	-$617K	﹤0.01%	1403
2026 Q1	$537K	Sell	3,178 -2,377	-43%	-$411K	﹤0.01%	850
2025 Q4	$740K	Hold	5,555	–	–	﹤0.01%	752
2025 Q3	$675K	Buy	5,555 +1,131	+26%	+$127K	﹤0.01%	823
2025 Q2	$462K	Buy	4,424 +2,686	+155%	+$284K	﹤0.01%	882
2025 Q1	$203K	Buy	+1,738	New	+$198K	﹤0.01%	1008
2021 Q2	–	Sell	-4,971	Closed	-$281K	–	1535
2021 Q1	$281K	Sell	4,971 -4,349	-47%	-$306K	﹤0.01%	1453
2020 Q4	$759K	Buy	9,320 +125	+1%	+$9.35K	﹤0.01%	1046
2020 Q3	$655K	Hold	9,195	–	–	﹤0.01%	982
2020 Q2	$757K	Buy	9,195 +830	+10%	+$63.9K	﹤0.01%	954
2020 Q1	$492K	Buy	+8,365	New	+$682K	﹤0.01%	908

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Los Angeles Capital Management's AXSM Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Axsome Therapeutics (AXSM) stake by 89% in Q2 2026, selling an estimated $617K and leaving 335 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #1403.

Los Angeles Capital Management first reported a position in AXSM in Q1 2020 and has held it in 11 quarters since. The position peaked at $759K in Q4 2020. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Los Angeles Capital Management held 335 shares of Axsome Therapeutics worth $82K as of Q2 2026.
Los Angeles Capital Management sold 2,843 Axsome Therapeutics shares in Q2 2026, an estimated $617K.
Axsome Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1403 holding.
Los Angeles Capital Management first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 11 quarters since.
Los Angeles Capital Management's Axsome Therapeutics position peaked at $759K in Q4 2020.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.